Unknown

Dataset Information

0

The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum.


ABSTRACT: Extensive control efforts have significantly reduced malaria cases and deaths over the past two decades, but in recent years, coupled with the COVID-19 pandemic, success has stalled. The WHO has urged the implementation of a number of interventions, including vaccines. The modestly effective RTS,S/AS01 pre-erythrocytic vaccine has been recommended by the WHO for use in sub-Saharan Africa against Plasmodium falciparum in children residing in moderate to high malaria transmission regions. A second pre-erythrocytic vaccine, R21/Matrix-M, was also recommended by the WHO on 3 October 2023. However, the paucity and limitations of pre-erythrocytic vaccines highlight the need for asexual blood-stage malaria vaccines that prevent disease caused by blood-stage parasites. Few asexual blood-stage vaccine candidates have reached phase 2 clinical development, and the challenges in terms of their efficacy include antigen polymorphisms and low immunogenicity in humans. This review summarizes the history and progress of asexual blood-stage malaria vaccine development, highlighting the need for novel candidate vaccine antigens/molecules.

SUBMITTER: Takashima E 

PROVIDER: S-EPMC10813614 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for <i>Plasmodium falciparum</i>.

Takashima Eizo E   Otsuki Hitoshi H   Morita Masayuki M   Ito Daisuke D   Nagaoka Hikaru H   Yuguchi Takaaki T   Hassan Ifra I   Tsuboi Takafumi T  

Biomolecules 20240112 1


Extensive control efforts have significantly reduced malaria cases and deaths over the past two decades, but in recent years, coupled with the COVID-19 pandemic, success has stalled. The WHO has urged the implementation of a number of interventions, including vaccines. The modestly effective RTS,S/AS01 pre-erythrocytic vaccine has been recommended by the WHO for use in sub-Saharan Africa against <i>Plasmodium falciparum</i> in children residing in moderate to high malaria transmission regions. A  ...[more]

Similar Datasets

| S-EPMC2491586 | biostudies-literature
| S-EPMC2883548 | biostudies-literature
| S-EPMC5658161 | biostudies-literature
| S-EPMC6558156 | biostudies-literature
| S-EPMC8279373 | biostudies-literature
| S-EPMC9996596 | biostudies-literature
| S-EPMC5772037 | biostudies-literature
| S-EPMC4169582 | biostudies-literature
| S-EPMC5602874 | biostudies-literature
| S-EPMC3704724 | biostudies-literature